{"filings":[{"id":1473156,"accession_number":"0001585364-26-000110","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K/A","filed_at":"2026-07-06T20:48:51+00:00","items":["5.02","9.01"],"status":"ready","headline":"Perrigo finalizes interim CEO Albert Manzone's compensation: $1.27M salary, $2.5M RSU grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Albert Manzone appointed Interim President and CEO effective June 7, 2026; fixed term through Dec 31, 2026, with possible 90-day extension.","Annual base salary of $1,270,000; one-time cash bonus of $250,000 subject to board-approved metrics.","One-time special RSU grant of $2,500,000 vesting upon earlier of one year, hiring of permanent CEO, or change of control.","If permanent CEO appointed before end of fixed term, Manzone receives full salary/benefits for fixed term and alternative role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1472997,"accession_number":"0001585364-26-000108","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2026-07-06T20:45:07+00:00","items":["5.02"],"status":"ready","headline":"Perrigo reinstates executive severance policy for transition period around CEO succession","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Policy reinstated effective June 29, 2026, covering executive officers except interim CEO and successor CEO.","Qualifying termination during transition period (June 7, 2026 to 12 months after new CEO starts) entitles 1.5x base salary + target bonus over 18 months.","Also includes COBRA premium payments, pro rata bonus based on actual performance, and career transition assistance.","Benefits subject to release of claims, confidentiality, non-compete, non-solicitation, and non-disparagement.","Policy terminates at end of transition period; signals CEO Patrick Lockwood-Taylor's succession is imminent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1362036,"accession_number":"0001585364-26-000103","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2026-06-30T20:46:51+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Perrigo appoints Salman Amin and Omer Gajial as independent directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board appointed Salman Amin (66) and Omer Gajial (52) as independent directors effective June 30, 2026.","Board size increased from 8 to 10; Amin to serve on Audit and Nominating/Governance, Gajial on Talent/Compensation.","Amin most recently CEO of pladis Global; Gajial currently CEO of GoTo Foods, previously EVP at Albertsons.","No arrangements or related-party transactions with either appointee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":918757,"accession_number":"0001193125-26-261809","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2026-06-08T20:22:48+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Perrigo CEO resigns after conduct violation; Board appoints Albert Manzone as interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patrick Lockwood-Taylor resigned as President, CEO, and Board member effective June 7, 2026, after Board found personal conduct violated Code of Conduct.","Albert A. Manzone, Board member since 2022, appointed Interim President and CEO; comprehensive search for permanent CEO initiated.","Resignation unrelated to Perrigo's business, strategy, operations, financial reporting, or results.","Company reaffirms FY2026 outlook: All In adj. EPS $2.00-$2.30, Core adj. EPS $2.25-$2.55, net sales growth (5.5)% to (1.5)%.","Manzone will step down from Audit Committee during his interim service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93874,"accession_number":"0001585364-26-000044","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Perrigo Q1 net sales $969M (-7.2%), adj EPS $0.43 (-28%); reaffirms FY 2026 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["All In net sales $969M, down 7.2% YoY; reported diluted EPS $(2.81) due to $330.8M goodwill impairment.","Core adjusted EPS $0.40, down 20% YoY; Core organic net sales -11.0% reflecting lower seasonal cough/cold and retailer destocking.","After quarter end, completed Dermacosmetics sale for upfront cash of €306M; proceeds to support debt reduction.","Self Care segment net sales down 11.5%, operating income down 39.3% due to lower volumes and prior-year manufacturing headwinds.","Full-year 2026 outlook reaffirmed; expects second-half improvement from lapping headwinds and OEP."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":969200000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93873,"accession_number":"0001193125-26-206401","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Perrigo shareholders approve 2026 LTIP, re-elect all director nominees at AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2026 Long-Term Incentive Plan approved (101.5M for); replaces 2019 Plan. Authorized pool: 7.265M new shares plus forfeitures.","All nine director nominees elected; strongest support for Kevin Egan (106.6M votes), lowest for Albert Manzone (92.1M).","Advisory 'say-on-pay' vote (105.4M for) and auditor ratification (113.5M for) passed.","Board authority to issue shares and opt-out of pre-emption rights under Irish law renewed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93872,"accession_number":"0001585364-26-000040","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Perrigo completes sale of Dermacosmetics business for €305.6M upfront, plus contingent €27M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash €305.6M (incl. €5.6M working capital); up to €27M contingent on net sales milestones over three years.","Brands sold: ACO, Biodermal, Emolium, Iwostin; business generated ~€120M net sales (~5% of adj. op income) in 2025.","Net proceeds will be used primarily for debt reduction, enhancing financial flexibility and strengthening balance sheet.","Divestiture is part of Perrigo's Three-S plan to Stabilize, Streamline, and Strengthen the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93871,"accession_number":"0001585364-26-000035","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Perrigo revises segment reporting; FY2025 includes $1.36B impairment charge","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Self Care segment net sales $2,533.5M in FY2025, down from $2,554.3M in FY2024.","Infant Formula segment net sales $359.0M in FY2025, down from $397.0M in FY2024.","Adjusted operating income for segments totaled $682.6M in FY2025, consolidated adjusted operating income $622.3M.","Q4 2025 goodwill impairment of $1.3B plus $33.6M equity method impairment contributed to reported operating loss of $1,122.2M.","Segment change effective Q1 2026; recast historical data provided for comparability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105840,"accession_number":"0001585364-26-000028","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Perrigo amends credit facility: $1.0B revolver (2031) & $972M term loan B (2029)","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered Amended and Restated Credit Agreement on March 20, 2026, with JPMorgan and others.","Revolving credit facility increased to $1.0B, maturing March 20, 2031; term loan B unchanged at $972.4M maturing April 20, 2029.","Proceeds from revolver drawdown used to prepay Term A Loans in full, plus accrued interest and fees.","Credit spread adjustment on revolving loans eliminated; maturity of revolver tied to 91 days before term loan or 4.900% notes if outstanding.","Covenants include max secured net leverage ratio and minimum cash interest coverage; secured by assets and equity interests of loan parties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105839,"accession_number":"0001585364-26-000006","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Perrigo Q4 adj. EPS $0.77 vs $0.93 YoY; records $1.3B goodwill impairment; FY2026 outlook $2.00-$2.30","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $1.11B (-2.5% YoY); reported EPS ($10.20) from $1.3B goodwill impairment.","FY2025 adj. EPS $2.75 (+7% YoY); organic net sales -2.4%.","FY2026 All-in adj. EPS guidance $2.00-$2.30; CORE adj. EPS $2.25-$2.55 (excl. infant formula and divestitures).","New operational enhancement program targets $80M-$100M in annualized pre-tax savings.","Potential additional goodwill impairment of up to $350M in Q1 2026 from reporting unit reallocation."],"consensus_eps_estimate":null,"consensus_eps_actual":-10.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":4253100000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122109,"accession_number":"0001585364-25-000153","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Perrigo Q3 adj EPS $0.80 flat YoY; cuts FY25 guide; starts infant formula review","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $1.04B (-4.1% YoY); adj EPS $0.80 vs $0.81; reported EPS $0.09 vs -$0.13.","FY25 outlook lowered: net sales growth -2.5% to -3.0%, adj EPS $2.70-$2.80 (5%-9% YoY growth).","Initiates strategic review of infant formula business; continues oral care review; Dermacosmetics sale on track for Q1 2026.","OTC store brand gained dollar, unit, and volume share in 5 of 7 categories despite soft market.","YTD adj operating income up 9.8% to $455M; benefits from Project Energize and Supply Chain Reinvention."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":3143500000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138827,"accession_number":"0001585364-25-000120","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Perrigo Q2 2025 Adj EPS $0.57 beats $0.53; net sales $1.06B down 0.9% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported EPS $0.00 vs $(0.77); Adj EPS $0.57 up 7.5% YoY on lower interest expense from reduced debt.","Net sales $1,056M down 0.9% YoY; organic net sales flat (-0.1%); CSCI organic +2.7%, CSCA organic -1.9%.","Reported operating income $45M vs $(27M) loss; Adj operating income $135M down 2.9% due to infant formula scrap and lower plant absorption.","Reaffirms FY2025 adj EPS target $2.90-$3.10; topline expected towards lower end of previous ranges.","Announced agreement to sell Dermacosmetics business, expected close Q1 2026; proceeds to strengthen balance sheet."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":2100200000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138826,"accession_number":"0001193125-25-158493","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Perrigo to sell Dermacosmetics business to KKR for up to €327M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash €300M, plus up to €27M milestone payments over three years.","Divestiture includes brands ACO, Biodermal, Emolium, Iwostin; 2024 net sales ~€125M.","Expected to close Q1 2026; net proceeds to strengthen balance sheet.","Advances Perrigo's 'Three-S' plan to streamline portfolio and focus on high-growth brands.","Business generated ~5% of Perrigo's 2024 adjusted operating income."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138825,"accession_number":"0001193125-25-154126","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Perrigo restructures leadership; Triona Schmelter departs, Roberto Khoury named EVP & CCO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Triona Schmelter, EVP & President Consumer Self-Care Americas, departs June 30 due to position elimination; remains advisory until Oct 31.","Roberto Khoury appointed EVP & Chief Commercial Officer effective July 1, from prior role leading Consumer Self-Care International.","Organizational alignment scales global category-led, market activation model; roles of EVP Pres CSCI and CSCA discontinued.","2025 adjusted EPS guidance unchanged; restructuring part of multi-year Stabilize, Streamline and Strengthen plan.","Perrigo notes growth model already delivering results in CSCI and increasingly in CSCA; aims to unlock brand and store brand portfolio value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156297,"accession_number":"0001193125-25-134980","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Perrigo EVP Global Ops Ron Janish to retire; Matt Winterman appointed as successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ron Janish steps down June 23, 2025; advisory role through Sep 30, 2025.","Janish receives 2.5x salary plus target bonus severance, equity vesting per agreement.","Matt Winterman named EVP Product Supply, Operations Strategy & Transformation Officer, effective June 23.","Winterman previously SVP Global Supply Chain at AstraZeneca, overseeing $54B supply chain.","Winterman also held supply chain leadership roles at Roche and GSK."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156296,"accession_number":"0001585364-25-000054","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Perrigo Reports Q1 2025 Adjusted EPS Up 106.9% to $0.60, Net Sales $1.04B Down 3.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales of $1.04B declined 3.5% due to divestitures and currency; organic net sales down 0.4%.","Adjusted EPS rose 106.9% to $0.60 from $0.29, driven by infant formula recovery and Project Energize savings.","Adjusted gross margin expanded 440 bps to 41.0%; adjusted operating margin up 550 bps to 14.0%.","Company widens 2025 net sales growth outlook to 0%-3% from 1%-3% due to tariff uncertainty; reaffirms adjusted EPS target.","Project Energize achieved $159M gross savings with $20M reinvestment since 2024; incurred $111M restructuring charges."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":1043900000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156295,"accession_number":"0001585364-25-000051","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Perrigo shareholders elect all 11 director nominees at May 1 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 board nominees elected; Albert A. Manzone received lowest support at 99.5M for vs. 14.9M against.","Ratification of Ernst & Young as auditor for FY 2025 passed with 120.5M for, 1.8M against.","Advisory say-on-pay vote passed with 112.6M for, 1.8M against, 8.3M abstain/broker non-votes.","Proposals to renew share issuance authority and pre-emption opt-out approved with >119M votes each.","Amendment to Articles of Association approved with 113.4M for, 0.9M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174752,"accession_number":"0001585364-25-000010","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Perrigo Q4 adj EPS $0.93 (+8.1% YoY); FY 2024 adj EPS $2.57 at guidance midpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $1.14B (-1.6% YoY); organic growth +0.7% despite lost distribution and later cold season.","Q4 adj operating income $194M (+16%); adj operating margin 260 bps expansion to 17.0% due to Project Energize.","Infant formula net sales +17% in Q4; store brand share exited 2024 at high; FDA Wisconsin facility reclassified to No Action Indicated.","FY 2024 operating cash flow $363M (103% conversion); fully repaid $400M 3.9% Senior Notes due Dec 2024.","Project Energize achieved $139M gross annual savings in 2024; target $140-170M by 2026; $95M restructuring charges incurred."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":4373400000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174751,"accession_number":"0001585364-25-000008","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Perrigo extends CEO Lockwood-Taylor through June 2028 with $1.24M salary and $6.6M LTI floor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary $1,240,000; target annual bonus at least 125% of base (0%-200% range).","Minimum annual LTI grant value of $6,600,000 under 2019 Plan.","Severance: 1.5x (salary+target bonus) non-CIC; 2.0x upon CIC within 24 months.","Noncompete and non-solicitation covenants for 24 months post-termination.","Initial term 3 years ending June 30, 2028, with automatic renewal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174750,"accession_number":"0001193125-25-019411","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Perrigo director Katherine Doyle to retire at 2025 AGM; no disagreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Katherine Doyle will not stand for re-election at 2025 annual general meeting and intends to retire.","She has served as an independent director since 2020, on Nominating & Governance and Talent & Compensation Committees.","Decision is not due to any disagreement with the company; she remains in role until AGM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174749,"accession_number":"0001585364-25-000003","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Perrigo appoints former Electrolux CEO Jonas Samuelson to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jonas Samuelson appointed to Perrigo board effective Jan 15, 2025; will serve on Audit and Nominating & Governance committees.","Samuelson previously served as President, CEO & board member of AB Electrolux and as CFO of Electrolux Group.","He also held CFO role at Munters AB and leadership roles at General Motors and Saab Automobile AB.","Samuelson will receive standard non-employee director compensation as described in company's 2024 proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191698,"accession_number":"0001585364-24-000147","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Perrigo reaches $98M D&O insurance settlement for securities litigation costs","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["D&O insurers will pay Perrigo $98M inclusive of costs before end of FY2024.","Settlement covers coverage obligations for securities litigation from 2015-2017 including opt-out cases.","Proceeds reimburse legal expenses and prior settlement of a class action in New Jersey federal court.","Perrigo will surrender 2015/2016 policies and withdraw claims under 2017/2018 policies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191697,"accession_number":"0001585364-24-000135","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Perrigo Q3 adjusted EPS $0.81 (+27% YoY); revenue -3.2%; reaffirms FY outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 adjusted EPS $0.81 (+26.6% YoY from $0.64); GAAP EPS ($0.13) vs $0.11 prior year.","Net sales $1.1B, -3.2% YoY; organic net sales -2.4% due to lost distribution of lower-margin products.","Adjusted operating margin 16.8% (+340bps YoY) driven by infant formula recovery, Project Energize.","Infant formula net sales +3% YoY, +58% sequentially; store brand non-WIC powder share gains.","Reaffirms FY2024 adjusted EPS outlook $2.50-$2.65; net sales expected towards lower end of prior range."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":3235100000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191696,"accession_number":"0001585364-24-000138","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K/A","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Perrigo Q3 adjusted EPS $0.81 (+26.6% YoY); net sales -3.2% to $1.09B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Adjusted EPS $0.81 vs $0.64 prior year; GAAP EPS loss $(0.13).","Net sales $1.088B, down 3.2% YoY; organic net sales -2.4% due to lost distribution of lower-margin products.","Adjusted gross margin 41.0% (+160bps), adjusted operating margin 16.8% (+340bps); margin expansion driven by infant formula recovery and Project Energize.","Infant formula net sales +3% YoY and +58% sequentially; Perrigo-produced store brand share gains +40bps.","FY2024 adjusted EPS guidance reaffirmed at $2.50-$2.65; redeemed $700M 4.375% senior notes due 2026 after quarter end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":3235100000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208177,"accession_number":"0001193125-24-220737","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Perrigo closes $715M USD and €350M senior notes offering; net proceeds ~$1.076B to refinance debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $715M 6.125% Senior Notes due 2032 and €350M 5.375% Senior Notes due 2032.","Net proceeds ~$1,076M; used to redeem all 4.375% Notes due 2026 and prepay Term B Loans.","Notes are unsecured senior obligations, guaranteed by Perrigo and certain subsidiaries.","Offering closed September 17, 2024; underwriters include BofA, J.P. Morgan, Wells Fargo, Morgan Stanley, HSBC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208176,"accession_number":"0001585364-24-000116","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Perrigo recalls 16,500 cans of infant formula over elevated vitamin D levels","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Voluntary recall of 3 lots of store-brand Premium Infant Formula with Iron Milk-Based Powder (16,500 cans).","Recalled product shipped to CVS (Feb 6-11, 2024) and H-E-B (Feb 2 – May 13, 2024); no other retailers affected.","Elevated vitamin D above maximum permitted; no adverse events reported to date.","Financial cost not expected to be material; no impact on Fiscal Year 2024 outlook provided Aug 2, 2024.","Recall initiated in consultation with FDA; consumers advised to check lot codes with use-by dates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208175,"accession_number":"0001585364-24-000111","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Perrigo Q2 net sales down 10.7% to $1.07B; adjusted EPS $0.53 vs $0.63; lowers FY sales outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net sales $1.07B, down 10.7% YoY; organic sales down 9.1% due to infant formula actions and lower seasonal demand.","GAAP operating loss $27M vs income $57M; adjusted operating income $139M up 1.5%.","Adjusted diluted EPS $0.53 vs $0.63; impacted by $0.09 discrete tax benefit in prior year and -$0.14 from infant formula.","FY24 organic net sales growth outlook lowered to -3% to -1% from +1% to +3%; total sales growth -5% to -3%.","FY24 adjusted diluted EPS reaffirmed $2.50-$2.65; Project Energize on track with $53M YTD savings."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":2147500000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208174,"accession_number":"0001193125-24-188915","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Perrigo board member Todd Penegor resigns to become CEO of another public company","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Todd Penegor resigned from Perrigo's board on July 24, 2024, effective July 31, 2024.","Penegor stated he expects to be named CEO of another public company, causing the departure.","He confirmed his resignation was not due to any disagreement with Perrigo's operations or policies.","Penegor had served as a director; his departure reduces board size by one member."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208173,"accession_number":"0001193125-24-177015","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Perrigo completes divestiture of HRA Pharma Rare Diseases to Esteve for up to €275M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration up to €275M: €190M upfront cash plus up to €85M in earnout based on sales milestones.","Proceeds to be redeployed for debt repayment; impact included in previously issued 2024 outlook.","Rare Diseases business had FY2023 net sales of ~€50M and adjusted EBITDA of ~€20M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225740,"accession_number":"0001193125-24-158363","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Perrigo appoints former Wendy's CEO Todd Penegor to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Todd Penegor appointed to Perrigo Board effective June 21, 2024.","Penegor will serve on the Board's Audit Committee.","Most recently served as CEO of The Wendy's Company (2016-2024) and earlier as CFO.","Prior leadership roles at Kellogg Company and Ford Motor Company spanning finance and strategy.","Compensation aligned with standard non-employee director package disclosed in March 2024 proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225739,"accession_number":"0001193125-24-148188","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Perrigo General Counsel Kyle Hanson steps down; Todd Kingma named interim","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kyle Hanson to step down as EVP, General Counsel and Corporate Secretary effective May 30, 2024.","Hanson will serve as Special Counsel through Sept 15, then advisory through Dec 31.","Receives severance: one year base salary, COBRA, bonus at target, equity vesting for 36 months, $180k relocation, and potential RSU grant up to $500k tied to securities litigation milestones.","Todd Kingma, retired after 19 years at Perrigo, appointed Interim EVP, General Counsel and Corporate Secretary effective May 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225738,"accession_number":"0001585364-24-000066","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Perrigo Reports Q1 2024 Adjusted EPS of $0.29, Above Projection; Net Sales Down 8.4%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net sales $1.1B, down 8.4% vs prior year; organic net sales declined 7.0% due to infant formula and SKU prioritization actions.","Adjusted diluted EPS of $0.29, $0.06 ahead of projection primarily from infant formula shipment timing; down from $0.45 YoY.","Reaffirms FY2024 outlook: organic sales growth 1%-3%, adjusted EPS range $2.50-$2.65, interest expense ~$180M.","Infant formula impacted adjusted gross margin by -280 bps and adjusted EPS by -$0.30 in the quarter.","Svend Andersen, EVP & President CSCI, to retire; Roberto Khoury appointed as successor effective August 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":1082100000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225737,"accession_number":"0001193125-24-132478","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Perrigo announces retirement of EVP Svend Andersen; appoints Roberto Khoury as successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Svend Andersen to retire as EVP & President, Consumer Self-Care International, effective July 31, 2024, then advisory role through Dec 31, 2024.","Roberto Khoury appointed as EVP & President, Consumer Self-Care International, effective Aug 1, 2024; starts May 20 for transition.","Khoury previously SVP & GM global skin care at Kenvue (formerly Johnson & Johnson).","Andersen eligible for lump sum severance of one year base salary plus prorated bonus and continued equity vesting per proxy.","Mutual agreement on retirement; Andersen will help ensure smooth transition with Khoury until July 31."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225736,"accession_number":"0001193125-24-130688","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":[],"status":"ready","headline":"Perrigo 2024 AGM results: all 10 director nominees elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders elected all 10 director nominees; votes for ranged from ~106.5M to ~115.5M.","Ratified Ernst & Young as auditor for FY2024, 119.8M for and 1.6M against.","Advisory vote on executive compensation passed with 112.9M for, 3.1M against.","Board authority to issue shares and opt-out of pre-emption rights both renewed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225735,"accession_number":"0001193125-24-111405","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Perrigo to sell HRA Pharma Rare Diseases to Esteve for up to €275M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration up to €275M: €190M cash plus up to €85M earnout on sales milestones.","Esteve Healthcare signed binding offer; Perrigo has a put option to finalize sale.","Transaction expected to close in Q3 2024, subject to Works Council consultation and regulatory approvals.","Sale includes HRA Pharma Rare Diseases business; Perrigo will proceed after French Works Council process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244878,"accession_number":"0001193125-24-060777","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Erica L. Mann to retire from Perrigo board at 2024 AGM","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erica L. Mann, 65, independent director since 2019, will not stand for re-election at 2024 AGM.","She serves on the Talent & Compensation Committee; decision not due to any disagreement.","Mann will continue as director until the 2024 annual general meeting; no replacement named."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244877,"accession_number":"0001585364-24-000005","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Perrigo Q4 adjusted EPS $0.86 (+14.7%); launches Project Energize","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $1.2B flat YoY; organic net sales -0.6% on SKU cuts and HRA distributor transitions.","Q4 adjusted gross margin expanded 140bps to 39.8%; adjusted diluted EPS $0.86 vs $0.75.","FY2023 net sales $4.7B (+4.6%); adjusted diluted EPS $2.58 vs $2.07 (+24.6%).","Launches Project Energize: three-year program targeting $140M-$170M annual savings by 2026; ~6% role reduction.","FY2024 outlook: organic net sales growth 1-3%, flat total sales; adjusted EPS $2.50-$2.65; infant formula headwinds."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":4655600000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262324,"accession_number":"0001193125-23-296684","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["1.01","8.01","2.03","9.01"],"status":"ready","headline":"Perrigo adds $300M incremental term loans, tenders $300M 2024 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Incremental Term B Loans of $300M added under existing credit agreement, maturing April 20, 2029.","Proceeds used to settle cash tender offer of $300M of 3.900% Senior Notes due 2024.","Tender offer accepted $300M notes on Dec 15, 2023, paying ~$295.1M plus accrued interest.","Terms of incremental loans substantially identical to existing 2022 Term B Loans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262323,"accession_number":"0001193125-23-284802","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2023-11-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perrigo early tender results: $300M of 3.900% notes due 2024 accepted at proration rate of 76.32%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$385.5M principal tendered; $300M accepted per tender cap of $300M, prorated at 76.32%.","Total consideration of $983.75 per $1,000 principal includes $30 early tender premium; accrued interest also paid.","Settlement expected December 15, 2023, subject to funding $300M incremental term loans.","Tender offer expires December 12, 2023; no notes tendered after Early Tender Date will be accepted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262322,"accession_number":"0001193125-23-275256","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Perrigo launches $300M tender offer for 3.900% Notes due 2024, financed by incremental term loans","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Tender offer up to $300M principal of $700M outstanding 3.900% Senior Notes due 2024.","Total consideration $983.75 per $1,000 principal ($953.75 + $30 early tender premium) plus accrued interest.","Concurrently seeking $300M incremental term loans under existing senior secured credit facilities.","Early tender date: Nov 28, 2023, 5:00 PM ET; expiration: Dec 12, 2023; expected settlement Dec 15, 2023.","Remaining outstanding Notes after tender to be repaid with cash on hand prior to maturity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262321,"accession_number":"0001585364-23-000139","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Perrigo Q3 adjusted EPS $0.64, revenue $1.1B; lowers FY23 sales guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $0.11 vs -$0.39; adjusted EPS $0.64 vs $0.56, up 14.3% YoY.","Reported net sales +2.2% to $1.1B; organic net sales -1.2% on SKU prioritization.","Adjusted gross margin 39.5% (+300bps); operating cash flow $125M.","CSCA net sales -2.6%, CSCI +11.2% (organic +6.2%).","FY23 guidance: reported net sales growth 4-6% (prev 7-11%), adj. EPS $2.50-$2.60 (prev $2.50-$2.70)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":3498700000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279518,"accession_number":"0001193125-23-232560","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2023-09-11T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Perrigo EVP & President, Consumer Self-Care Americas departs; successor named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Dillard III mutually separated as EVP & President, Consumer Self-Care Americas effective Sept 11, 2023; advisory role through Sept 30.","Severance includes one year base salary, prorated bonus, COBRA, continued equity vesting; offset provision for Irish tax equalization.","Catherine \"Triona\" Schmelter appointed as EVP and President, Consumer Self-Care Americas and Global Portfolio Optimization effective Sept 11.","Schmelter most recently Chief Transformation Officer at TreeHouse Foods, focused on growth acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279517,"accession_number":"0001585364-23-000126","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Perrigo appoints Julia Brown to board of directors, effective Nov 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Julia Brown appointed to Perrigo board, effective November 1, 2023.","Most recently served as Chief Procurement Officer for Mars Wrigley (2020-2021).","Previously Chief Procurement Officer at Carnival Corporation & plc (2015-2020).","Compensation follows standard non-employee director pay as disclosed in March 2023 proxy.","No arrangements or understandings with any person regarding her selection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279516,"accession_number":"0001585364-23-000120","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Perrigo Q2 adjusted EPS $0.63 beats $0.43 prior year; margins expand 220bps; FY outlook reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net sales $1.2B, +6.4% reported; organic growth 0.8% as SKU prioritization (-2.7pp) and weaker allergy season offset pricing.","Adjusted diluted EPS $0.63 (+46.5% YoY); includes $0.08 discrete tax benefit and $0.05 HRA transition returns headwind.","Adjusted gross margin 38.7% (+220bps YoY, +120bps QoQ); operating income $57M GAAP vs $(7M) prior year.","CSCA organic sales -2.7% (SKU cuts -4.1pp, allergy -1.8pp); CSCI organic +7.1% on pricing and HRA.","FY2023 outlook reaffirmed: organic sales growth 3-6%, adjusted EPS $2.50-$2.70; Opill pre-launch investments included."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":2374800000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297917,"accession_number":"0001193125-23-163039","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Perrigo appoints Patrick Lockwood-Taylor as CEO, effective June 30, 2023; Murray Kessler retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patrick Lockwood-Taylor, 54, becomes President, CEO and director, effective June 30, 2023, succeeding Murray Kessler who retires.","Lockwood-Taylor joins from Bayer AG, where he was President of Consumer Health North America and President of Bayer U.S.","Base salary of $1,200,000; target annual bonus of at least 120% of salary; sign-on equity awards: $2.8M RSUs and $1.5M PSUs.","Annual long-term incentive grants of at least $5.6M beginning 2024.","Kessler will remain in advisory role through July 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297916,"accession_number":"0001585364-23-000061","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Perrigo AGM: directors elected, say-on-pay passes with 33% dissent","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 10 director nominees elected; Erica L. Mann received 16,336,273 votes against (~14%).","Advisory vote on executive compensation passed with 77,848,010 for, 38,080,510 against (33% opposition).","Say-on-pay frequency set at 1 year with 107,429,468 votes for that option.","Ratification of Ernst & Young as auditor for FY2023 approved: 122,552,222 for, 697,972 against.","Shareholder-approved creation of distributable reserves and renewal of board authority to issue shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297915,"accession_number":"0001585364-23-000055","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Perrigo Q1 adj EPS $0.45 (+35.6% YoY); IRS resolves $843M claim; CEO to step down","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $1.2B (+10.0% YoY); organic net sales +6.4%; CSCI segment achieved record sales with constant currency growth of 23.6%.","GAAP EPS loss $(0.01); adjusted diluted EPS $0.45, up from $0.33 (35.6% increase). Adjusted gross margin expanded 400 bps to 37.5%.","IRS NOPA of $843 million fully withdrawn with no payment required; interest rate NOPA also settled.","CEO Murray Kessler announces plan to transition to a next-generation leader; no successor or timing announced.","FY2023 guidance reaffirmed: organic net sales growth 3%-6%, adjusted diluted EPS $2.50-$2.70."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":1181700000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297914,"accession_number":"0001193125-23-138849","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Perrigo CEO Murray Kessler to retire July 31, 2023; successor search underway","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Murray Kessler to retire effective July 31, 2023, after nearly 5 years leading transformation to consumer self-care.","Board has initiated CEO succession search with global executive search firm; no successor named yet.","Kessler cites completion of 14 M&A deals, elimination of $4B tax/legal overhang, and strategic plan in place.","Chairman Orlando Ashford thanks Kessler, expresses confidence in finding world-class CEO to execute Optimize and Accelerate plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297913,"accession_number":"0001585364-23-000051","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2023-04-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Perrigo resolves $843M IRS tax dispute; no payment required","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["IRS fully withdraws proposed $843M in tax adjustments and penalties for Athena's 2011-2013 tax years.","US Competent Authority closes case; Perrigo owes nothing on the Tysabri royalty transfer pricing issue.","Perrigo to release previously established reserves in Q2 FY2023, boosting earnings.","Resolution ends multi-year MAP process under U.S.-Ireland tax treaty.","Company says any prior uncertainty on Tysabri royalty tax treatment is now completely resolved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318157,"accession_number":"0001585364-23-000003","cik":1585364,"company_name":"PERRIGO Co plc","ticker":"PRGO","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Perrigo Q4 adj EPS $0.75 (+25% YoY); FY net sales $4.5B (+7.6% reported, +12.8% constant currency)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $1.2B (+4.6% reported, +9.6% constant currency); organic net sales +1.5%.","Q4 GAAP EPS loss ($0.09) vs prior year $0.24; adjusted EPS $0.75 (+25% YoY); constant currency adj EPS $0.80 (+33.3%).","FY2022 net sales $4.5B (+7.6% reported, +12.8% constant currency); organic net sales +8.8%.","FY2022 GAAP EPS loss ($0.97) vs prior year loss ($0.98); adjusted EPS $2.07 vs $2.06; constant currency adj EPS $2.31 (+12.1%).","Company to hold virtual Investor Day on Feb 28, 2023 to provide 2023-2025 strategic plan and fiscal 2023 guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":4451600000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1576008848.044803,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-02-27T23:59:59+00:00|318157"}